LINCOLN636.70

Lincoln Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSIGACHITHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYAHCLMcap ₹1,275 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation10.612.914.5
+ Finance Costs1.51.91.0
+ Interest Income-7.0-7.2-7.6
+ Dividend Income0.0-0.1-0.3
+ Fair Value (Gains) / Losses-21.1-4.2-0.3
+ Other Non-cash Items0.6-0.3-0.9
+ Other Reconciling Items-1.4-2.0-0.1
Changes in Working Capital
+ Inventories-7.1-1.5-1.4
+ Trade Receivables — Current-26.1-4.85.8
+ Other Financial Assets — Current0.10.1-0.2
+ Other Financial Assets — Non-current0.1-0.2-0.1
+ Other Current Assets-4.8-5.52.9
+ Other Non-current Assets0.4-0.40.1
+ Trade Payables — Current21.612.5-0.1
+ Other Financial Liabilities — Current0.51.01.2
+ Other Financial Liabilities — Non-current-1.11.80.7
+ Other Current Liabilities0.62.4-2.3
+ Provisions — Current-0.33.72.9
Cash from Operating Activities
Profit Before Tax (per I/S)122.2109.2115.6127.8
+ Total Adjustments (incl. Working Capital)-32.910.115.9
Cash from Operations (pre-tax)89.4119.3131.5
+ Income Taxes Paid26.226.325.1
Cash from Operating Activities63.293.0106.4
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)39.519.025.4
+ Acq of Intangible Assets0.00.00.6
+ Disp of Fixed Assets0.10.01.5
+ Acq of Investment Property99.685.169.1
+ Disp of Investment Property74.856.536.2
+ Loans & Advances Made97.053.096.7
+ Loans & Advances Repaid55.014.356.1
+ Dividends Received — Investing0.00.00.3
+ Interest Received — Investing9.03.70.9
+ Other Inflows / (Outflows) — Investing39.93.7-1.6
Cash from Investing Activities-57.3-78.9-98.4
Cash from Financing Activities
+ Proceeds from Borrowings20.068.40.0
+ Repayment of Borrowings20.969.4-4.4
+ Dividends Paid3.03.63.6
+ Other Inflows / (Outflows) — Financing-1.3-1.8-0.7
Cash from Financing Activities-5.2-6.40.2
Net Changes in Cash (pre-FX)0.77.78.1
Net Changes in Cash0.77.78.1
Closing Cash5.7
Reference Items
EBITDA99.9101.597.7101.3
EBITDA Margin %17.2116.2914.5614.59
Free Cash Flow (CFO − Capex)23.774.080.380.3
Free Cash Flow to Equity72.984.7
Free Cash Flow per Basic Share11.8536.9440.1040.10
Price to Free Cash Flow15.88
Cash Flow to Net Income0.681.131.21
Cash Paid for Taxes26.226.325.1
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.